This study evaluates the longevity of Descemet membrane endothelial keratoplasty (DMEK) grafts in terms of endothelial survival and endothelial failure.
S ince its introduction in 1998, endothelial keratoplasty has become increasingly popular and evolved from deep lamellar endothelial keratoplasty to Descemet stripping endothelial keratoplasty (DSEK) and Descemet stripping automated endothelial keratoplasty (DSAEK), and most recently to Descemet membrane endothelial keratoplasty (DMEK). 1 Although DMEK provides excellent visual acuity recovery of 20/25 or even better in about three-quarters of the eyes, [2] [3] [4] there is not yet any indication of long-term graft survival (ie, ≥10 years) in DMEK or earlier endothelial keratoplasty techniques. We recently reported an 84% graft survival rate at 10 years in our first deep lamellar endothelial keratoplasty cohort. 5 For DSEK/DSAEK, survival rates up to 5 years postoperatively seem to resemble midterm graft survival rates after penetrating keratoplasty (PK). [6] [7] [8] [9] [10] [11] [12] [13] [14] Midterm evaluation of endothelial cell density (ECD) after DMEK showed a 7% annual decrease that may mimic that of earlier endothelial keratoplasty techniques, while the decrease appears to be slower than after PK. [15] [16] [17] This may hint toward a higher endothelial survival probability after DMEK. If so, not only faster visual rehabilitation but also higher longterm endothelial survival would be important considerations for surgeons to choose DMEK over PK as a preferred treatment method in corneal endothelial disease. The aim of this study was to assess midterm endothelial survival by evaluating ECD decay and endothelial graft failures in the first DMEK cohort worldwide and to evaluate its association with the indication for surgery (Fuchs endothelial corneal dystrophy [FECD] vs bullous keratopathy [BK] ) and the presence of a partial graft detachment.
Methods
This was a retrospective cross-sectional study of data that had been collected from August 8, 2006, until June 17, 2015 , of 500 consecutive eyes that underwent DMEK in 395 patients (including the learning curve of the first 25 DMEK procedures).
Of each patient with bilateral DMEK, the second eye that underwent surgery was excluded from the analysis (n = 106). Because reliable ECD measurements could not always be obtained in eyes with a larger graft detachment (more than onethird of the graft surface area), only eyes with a detachment of one-third of the graft surface area or less (partially detached) were determined as a cutoff point for inclusion in the study. Hence, 40 eyes with a larger detachment were excluded, as were 2 eyes with DMEK performed as a secondary procedure after PK. Thus, 352 unilateral eyes that underwent DMEK in 352 patients were included in our study ( Table 1) .
Of these 352 eyes, 314 underwent DMEK for FECD, 31 underwent DMEK for BK (pseudophakic BK, aphakic BK, congenital glaucoma, phakic intraocular lens, or trauma), and 7 underwent DMEK as a secondary procedure to manage low visual outcome or graft failure after DSEK/DSAEK (Table 1) . Sixteen eyes (4.5%) had preexisting glaucoma (FECD, n = 7; BK, n = 8; failed DSEK/DSAEK, n = 1), of which 4 had congenital glaucoma. In total, 314 eyes had an attached graft and 38 had a partially detached graft ( Table 1 ). The mean (SD) participation time after DMEK was 42 (22) months (range, 0-96 months) ( Table 1) .
This study was approved by the institutional review board of the Netherlands Institute for Innovative Ocular Surgery as a retrospective data review. All patients signed an institutional review board-approved informed consent form. The study was conducted according to the Declaration of Helsinki. 18 
Donor Tissue
Harvesting of the Descemet membrane graft was performed as previously described. 19, 20 In short, corneoscleral buttons from donor globes were obtained post mortem and stored in organ culture medium at 31°C. In the eye bank, endothelial cell morphology and viability were evaluated and the corneoscleral buttons were mounted endothelial side up on a custommade holder so that a 9.5-mm-diameter Descemet membrane sheet with its endothelium could be stripped from the posterior stroma. Due to the elastic tissue properties, a Descemet roll formed spontaneously with the endothelium on the outside. Descemet rolls were then stored in organ culture medium until the day of transplantation (Table 1) .
Surgery
A circular 9.0-mm-diameter descemetorhexis was performed under air by scoring and stripping the Descemet membrane from the posterior stroma with a reversed Sinskey hook (D.O.R.C. International). In eyes that underwent DMEK as a secondary procedure, the primary DSEK/DSAEK graft was carefully removed from the recipient posterior stroma with a reversed Sinskey hook. The donor Descemet roll was stained with 0.06% Trypan blue solution (VisionBlue; D.O.R.C. International), sucked into a custom-made injector (DMEK inserter; D.O.R.C. International), and injected through a 3.0-mm limbal tunnel incision into the recipient anterior chamber. The graft was oriented with the endothelial side facing the recipient iris and with the donor Descemet membrane facing the recipient stroma. After complete graft unfolding over the iris through indirect manipulation by an air bubble, by flushing with balanced salt solution, and by gentle strokes on the corneal surface, an air bubble was injected under the graft to attach and fixate it onto the recipient posterior stroma. The anterior chamber was then completely filled with air for 60 minutes followed by an airliquid exchange, leaving a 30% to 50% air bubble.
21

At a Glance
• Endothelial cell survival and graft longevity after Descemet membrane endothelial keratoplasty show promising results. • Endothelial graft failure seems to mainly occur in eyes with concomitant ocular pathology.
• Results suggest that eyes with a partial graft detachment and eyes with bullous keratopathy show higher endothelial cell density decay, whereas eyes with Fuchs endothelial corneal dystrophy with a completely attached graft may have an excellent prognosis.
Postoperative medication included topical antibiotics for 2 weeks and a steroid regimen of dexamethasone sodium phosphate, 0.1%, eyedrops 4 times daily for 4 weeks, followed by fluorometholone eyedrops 4 times daily, tapered to once daily until 1 year postoperatively and thereafter once daily or once every other day. 22 
Data Collection
Donor ECD was measured preoperatively in vitro using an inverted light microscope (Axiovert 40; Zeiss) and postoperatively every 6 months up to 8 years with an SP3000p noncontact autofocus specular microscope (Topcon Medical Europe BV). At the same time intervals, all eyes had routine examina- tions, including biomicroscopy, anterior segment optical coherence tomography (Heidelberg Engineering GmbH), and Scheimpflug imaging (Pentacam; Oculus). Analysis of ECD was done by multiple trained technicians. For every image, the automatically delineated cell borders were carefully checked. If they were not correctly assigned by the program, a manual correction was applied to correctly assign the cell borders. Three central images were analyzed per eye and follow-up point and results were averaged. For every analysis, the largest possible part of the image was used.
Endothelial graft failure was diagnosed with slitlamp biomicroscopy, revealing corneal edema that necessitated repeat keratoplasty. Primary graft failure was defined as absent corneal clearance after surgery despite full graft attachment; secondary graft failure was defined as a corneal decompensation after a postoperative interval with a clear cornea.
To determine whether the indication for surgery affected the outcomes, the FECD subgroup was compared with the BK subgroup ( Figure 1B and Figure 2B ).
For each eye, graft adherence status was categorized as either completely attached or partially detached. These 2 subgroups were compared with each other to determine whether partial graft detachment affected ECD decay and endothelial survival ( Figure 1C and Figure 2C ).
Statistical Analysis
Participation time of an eye was defined as the time from surgery until the last visit with a successful graft or a failed graft necessitating repeat keratoplasty.
Linear mixed models were used to identify possible differences in ECD outcomes over 8 years between the different subgroups, FECD vs BK and attached vs partially detached grafts, while controlling for possible confounders of the patient (age, sex, lens status, preoperative glaucoma), the donor (cause of death, sex, age), and the donor and graft processing times (times from death to preservation, preservation to preparation, preparation to surgery). Examination of the residuals did not reveal violations of the assumptions (normality, homoscedasticity, outliers). There were a few eyes with high standardized residuals (between 3.5 and 4.0), for which the model does not fit well. Because 17 of 352 eyes did not have any follow-up ECD value at 6 months and onward, only the remaining 335 eyes could be included in the linear mixed model ECD analysis.
Based on the observed survival times of all eyes up to 8 years, survival distributions were estimated using the KaplanMeier estimator. Survival times were assessed with Cox regression while taking possible risk factors (age, preoperative ECD, etc) into account, to evaluate whether preoperative indication (FECD vs BK) and graft adherence status (attached vs partially detached) have an effect on survival time. Survival analysis for the entire group comprised 352 eyes; survival analysis for the subgroups comprised 345 eyes because the small regraft group (n = 7) was not included.
Statistical analyses were performed with R version 3.1.3 statistical software (R Foundation for Statistical Computing) using the package "survival," "rms," and "nlme."
Results
Endothelial Survival in Terms of Endothelial Decay
In the cross-sectional analysis of 352 eyes, the mean (SD) ECD was 1626 (507) Of the available eyes with survived (clear) grafts 7 years after DMEK, 5.0% had an ECD of less than 500 cells/mm 2 and 45.0%
had an ECD of 1000 cells/mm 2 or more ( Table 2 ).
In the longitudinal ECD analysis of 86 eyes with available ECD at each point from 6 months until 5-year follow-up, the mean (SD) ECDs at 6, 12, 24, 36, 48, and 60 months after DMEK were 1776 (555), 1674 (549), 1508 (534), 1377 (530), 1259 (504), and 1145 (483) cells/mm 2 , respectively ( Figure 1A ).
Up to 8 years, a significantly higher ECD was found in eyes with FECD than in those with BK (estimated mean difference, 261 cells/mm 2 ; 95% CI, 118-404; P = .003) ( Figure 1B ), and eyes with attached grafts had a significantly higher ECD than those with partially detached grafts (estimated mean difference, 330 cells/mm 2 ; 95% CI, 208-452; P < .001) ( Figure 1C ). The graft was partially detached in 35 of 314 eyes with FECD (11.1%) and in 3 of 31 eyes with BK (9.7%).
The risk factor preoperative ECD had an effect on the outcome ECD: for each additional 100 cells/mm 2 before DMEK, the final ECD outcome at 8 years postoperatively increased by an average of 86 cells/mm 2 (95% CI, 69-104; P < .001). Among the donor death causes (cancer, cardiac or stroke, respiratory, and trauma or other), cancer was associated with the highest ECD outcome until 8 years. When compared with the baseline category cardiac or stroke, the estimated mean difference was 133 cells/mm 2 (95% CI, 43-224; P = .01).
Endothelial Survival in Terms of Primary and Secondary Graft Failures
Endothelial failure occurred in 11 of 352 eyes (3.1%) within 4 years after DMEK; 4 eyes were diagnosed as having primary graft failure and 7 were diagnosed as having secondary graft failure. All of these eyes had concomitant ocular pathology, including partial graft detachment. Based on the number of primary and secondary graft failures in the entire cohort, the estimated survival probability was 0. ciated with glaucoma episodes necessitating filtering surgery. One eye that had DMEK for corneal decompensation due to congenital glaucoma in the presence of a brunescent cataract and a Baerveldt shunt developed graft failure after phacoemulsification 9 months after DMEK. Two eyes developed secondary graft failure after allograft rejection, and 2 eyes had an A-C, Survival probabilities and 95% confidence intervals for the overall group (A), for those with preoperative indication of Fuchs endothelial corneal dystrophy vs bullous keratopathy (B), and for those with attached grafts vs partially detached grafts (C). detachment at 6 months.
All other corneas with postoperative complications potentially affecting endothelial cell survival remained clear throughout the study period: reversible allograft rejection (n = 6), rebubbling (n = 4), postoperative glaucoma (n = 14), pars plana vitrectomy (n = 1), and phacoemulsification (n = 10).
Discussion
In PK and DSEK/DSAEK, graft survival has been described to vary with factors such as the indication for surgery, retransplantation, comorbidity (eg, glaucoma), complications (eg, allograft rejection), and donor characteristics. 10, 13, 14, 23, 24 To determine the causes associated with graft longevity in DMEK, we evaluated endothelial survival in terms of ECD decay and endothelial failure in a first DMEK cohort up to 8 years postoperatively. However, comparisons between studies require caution because graft survival may vary per region, demographic characteristics, and surgical setting and because various studies used different inclusion and exclusion criteria, causing varying survival outcomes. 25, 26 A complicating factor is the terminology used: graft survival may not mirror graft failure because technical failures may not provide information on the graft viability (eg, grafts positioned upside down have been shown to carry healthy endothelial cells). 27 Similarly, a common indication for repeat DMEK is graft detachment, but microscopic analysis of explanted grafts showed a normal and viable endothelial cell layer. 27 For that reason, we did not define our outcome measurements in terms of success rate or graft survival but instead based our analysis on ECD decay and on eyes with endothelial graft failure.
Endothelial Survival in Terms of Primary and Secondary Graft Failure
For DSAEK, a 3-year graft survival rate of 87% to 97% has been reported 6, 7 ; for DSEK, a 5-year survival rate of 93% has been reported. 8 After PK, survival rates may vary from 75% to 95% at 3 and 5 years. 6, 7, 9, 10 The overall DMEK survival probability in our cohort was 0.96 at 5 and 8 years postoperatively. Interestingly, all 11 endothelial graft failures in our study seemed to only be associated with surgical error, comorbidity, or postoperative complications. Of the 4 eyes that showed a primary graft failure, 3 were within the first 25 DMEK operations (learning curve), and these eyes may have undergone reoperation too early when the cornea failed to clear within 3 weeks. We later learned that in the presence of a completely attached graft, some transplanted corneas may need a longer time to clear. 28 The remaining eye with primary graft failure had a history of BK after penetrating ocular trauma. Eyes that developed a secondary graft failure had a partial graft detachment with a low ECD, BK after phakic intraocular lens implantation (and removal) complicated by glaucoma episodes, congenital glaucoma, or allograft rejection preceding the transplant failure. These findings would suggest that, overall, mainly eyes with comorbidity are at risk for graft failure or, in other words, that endothelial survival probability would be high in eyes that have undergone DMEK without complication. Compared with PK, survival probabilities with DMEK may have improved owing to elimination of suture-related complications (suture loosening, sterile inflammation, stromal melt), lower incidence of allograft rejection, better preservation of the anterior chamber angle anatomy, and faster tapering of steroids (reducing the risk of glaucoma and cataract formation). 22, 29, 30 When stratified by the indication for surgery, graft survival probability in terms of endothelial failure until 8 years after DMEK was better in eyes with FECD than in those with When analyzed for graft adherence status, the graft survival probability in eyes with a completely attached graft was higher than in those with a partial detachment (0.97 vs 0.91, respectively). Still, partial graft detachment did not seem to be significantly associated with higher risk of endothelial graft failure. This could be attributed to the relatively low number of eyes with endothelial failure in our cohort. Larger series in longer follow-up studies may be required to evaluate whether partial graft detachment is associated with a higher risk of endothelial failure.
It stands to reason that in both BK and partial graft detachment, a relative depletion of cells and/or the underlying pathology relates to lower endothelial survival rates. If so, partial graft detachment-albeit visually insignificant-could benefit from (earlier) surgical intervention, although repeat rebubbling has also been associated with lower ECDs. 31 Furthermore, the distribution of endothelial graft failures over time may be of interest: 6 of the 11 failures occurred within the first postoperative year. This may suggest that if the early postoperative course after DMEK is uneventful, the graft may have an excellent prognosis on long-term survival, especially in eyes with FECD, because late-onset secondary graft failure was consistently associated with comorbidity unrelated to the transplant itself. However, identification of risk factors was limited by the relatively small number of failures in our cohort combined with the amount of censored observations.
Endothelial Survival in Terms of ECD Decay
In addition to visual outcomes surpassing those of PK and DSEK/DSAEK, the relatively low number of endothelial failures in our study may suggest that DMEK also has the advantage of longer graft longevity. To further substantiate this hypothesis, we evaluated the decay in ECD during the first 8 years in an attempt to calculate how many eyes that underwent DMEK would have an ECD less than 500 cells/mm 2 , an ECD that may be associated with impending graft failure. 17, 32 Within the entire cohort of survived clear grafts, fewer than 10% of eyes had an ECD less than 500 cells/mm 2 at each follow-up point. Any predictions of a time at which low ECD may result in graft failure and whether a certain ECD constitutes a threshold related to graft failure seem unreliable because the longterm sample size was relatively small. A larger data set may be necessary to allow a reliable prediction on long-term endothelial survival after DMEK. 33 
Conclusions
This study shows that until 8 years after DMEK, endothelial survival may be promising. In particular, eyes with FECD and a completely attached graft may have an excellent prognosis in the longer term. 
